Joan Rosello-Catafau

Prof. Joan Rosello-Catafau

Experimental Pathology Department, Instituto de Investigaciones Biomédicas de Barcelona, Spanish Research Council (IIBB-CSIC), Rosselló 161, 08036-Barcelona, Catalonia, Spain.

Research Focus & Metrics

Academic Career Length

38Years (1989-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 April 1997 in Hepatology
Verified
Journal Article
Open access
PDF file
Carmen PeraltaCarmen Peralta
Carmen Peralta
GHGeorgina Hotter
Georgina Hotter
DCD Closa
D Closa
EGE Gelpí
E Gelpí
OBO Bulbena
O Bulbena
Joan Rosello-CatafauJoan Rosello-Catafau
Joan Rosello-Catafau
The effects of ischemic preconditioning on rat liver integrity, as well as the implication of nitric oxide (NO) and adenosine in this process, has been evaluated. Preconditioning before ischemia-reperfusion prevented the increases in alanine transaminase (ALT), aspartate transaminase (AST), and lactate dehydrogenase (LDH) levels, but did not modify blood flow. Adenosine or NO administration previous to hepatic ischemia-reperfusion simulated the effect of preconditioning, whereas inhibition of adenosine or NO synthesis abolished the protective effect of hepatic preconditioning. Nevertheless, inhibition of adenosine and simultaneous administration of NO in preconditioned animals offered similar results to those found in the preconditioned group, indicating that, in the absence of adenosine, NO is able to maintain the preconditioning benefits. It is suggested that, in preconditioning, adenosine stimulates NO production to protect against the injury associated with ischemia-reperfusion.

1 October 2006 in Life Sciences
Verified
Journal Article
Closed access
ACAraní Casillas-Ramírez
Araní Casillas-Ramírez
IMIsmail Ben Mosbah
Ismail Ben Mosbah
FRFernando Silva Ramalho
Fernando Silva Ramalho
Joan Rosello-CatafauJoan Rosello-Catafau
Joan Rosello-Catafau
Carmen PeraltaCarmen Peralta
Carmen Peralta

1 August 2002 in The American Journal of Pathology
Verified
Journal Article
Closed access
ASAnna Serafín
Anna Serafín
Joan Rosello-CatafauJoan Rosello-Catafau
Joan Rosello-Catafau
NPNeus Prats
Neus Prats
CXCarme Xaus
Carme Xaus
EGEmilio Gelpí
Emilio Gelpí
Carmen PeraltaCarmen Peralta
Carmen Peralta

1 January 2001 in Hepatology
Verified
Journal Article
Closed access
PDF file
Carmen PeraltaCarmen Peralta
Carmen Peralta
LFLeticia Fernández
Leticia Fernández
JPJulià Panés
Julià Panés
NPNeus Prats
Neus Prats
MSMiquel Sans
Miquel Sans
Joan Rosello-CatafauJoan Rosello-Catafau
Joan Rosello-Catafau
Previous studies indicate that ischemic preconditioning protects against lung injury resulting from hepatic ischemia–reperfusion (I/R) through inhibition of tumor necrosis factor (TNF) release from Kupffer cells. The present study investigated whether this effect is limited to the lung or is a generalized systemic response and explores the molecular mechanisms involved. Hepatic I/R led to an increase in neutrophil accumulation in liver, lung, and splanchnic organs. Although preconditioning did not modify neutrophil infiltration in liver during reperfusion, it conferred protection against hepatic injury associated with I/R. In remote organs, preconditioning abrogated the increase in P–selectin up–regulation, preventing neutrophil infiltration and thus reducing the oxidative stress and microvascular disorders following hepatic I/R in these organs. Administration of Abs against P–selectin or TNF previous to ischemia had the same effects as preconditioning. The effects of preconditioning on the blockade of P–selectin up–regulation probably results from inhibition of systemic TNF release from Kupffer cells. Supplementation of TNF abolished the benefits of preconditioning, whereas the injurious effects of TNF were prevented by previous blockade of P–selectin. The results of the present study suggest that ischemic preconditioning protects the liver against I/R injury by a mechanism independent of adhesion molecule expression and neutrophil accumulation. In remote organs, however, hepatic preconditioning prevents inflammatory damage by reducing the systemic TNF release from the liver and thus preventing P–selectin up–regulation.

1 January 1999 in Hepatology
Verified
Journal Article
Open access
PDF file
Carmen PeraltaCarmen Peralta
Carmen Peralta
GHGeorgina Hotter
Georgina Hotter
DCDaniel Closa
Daniel Closa
NPNeus Prats
Neus Prats
CXCarme Xaus
Carme Xaus
Joan Rosello-CatafauJoan Rosello-Catafau
Joan Rosello-Catafau
This study aims to determine if the protective role of adenosine in liver ischemic preconditioning is mediated by the activation of adenosine receptors and to ascertain which of these receptors is implicated in the process. Administration of adenosine A1 and A2 receptor antagonists to preconditioned animals indicates that hepatic preconditioning is mediated by the activation of adenosine A2 receptors. Propentofylline (an inhibitor of adenosine transport into cells) in the preconditioned group, subjected to previous administration of an adenosine A2 receptor antagonist, prevented the negative effect of the latter on the protection offered by preconditioning. An increase of NO production was detected just immediately after hepatic preconditioning, and the administration of an adenosine A2 receptor antagonist to the preconditioning group prevented this increase, thus abolishing the protective effect of preconditioning. However, the administration of a NO donor to the preconditioned group subjected to previous administration of the adenosine A2 receptor antagonist was able to maintain the preconditioning effects. In conclusion, these results indicate that, in preconditioning, the protective effect of adenosine could be a result of an increase in extracellular adenosine. This in turn would induce the activation of adenosine A2 receptors, which, by eliciting an increase in NO generation, would protect against the injury associated with hepatic ischemia–reperfusion.

1 December 2001 in Hepatology
Verified
Journal Article
Closed access
Carmen PeraltaCarmen Peralta
Carmen Peralta
RBRamón Bartrons
Ramón Bartrons
ASAnna Serafin
Anna Serafin
CBCristina Blázquez
Cristina Blázquez
MGManuel Guzmán
Manuel Guzmán
Joan Rosello-CatafauJoan Rosello-Catafau
Joan Rosello-Catafau
Hepatic ischemia-reperfusion (I/R) injury associated with liver transplantation and hepatic resections are an unresolved problem in the clinical practice. Preconditioning is known to preserve energy metabolism in liver during sustained ischemia, but the molecular mechanisms underlying this effect are still unclear. Different metabolic signals, including adenosine monophosphate (AMP) and nitric oxide (NO), have been implicated in preconditioning. AMP-activated protein kinase (AMPK) protects cells by acting as a low-fuel warning system, becoming switched on by adenosine triphosphate (ATP) depletion. NO synthesis is induced by AMPK in the heart during ischemia. The aim of this study was to investigate: 1) whether preconditioning induces AMPK activation; and 2) if AMPK activation leads to ATP preservation and reduced lactate accumulation during prolonged ischemia and its relationship with NO. Preconditioning activated AMPK and concomitantly reduced ATP degradation, lactate accumulation, and hepatic injury. The administration of an AMPK activator, AICAR, before ischemia simulated the benefits of preconditioning on energy metabolism and hepatic injury. The inhibition of AMPK abolished the protective effects of preconditioning. The effect of AMPK on energy metabolism was independent of NO because the inhibition of NO synthesis in the preconditioned group and the administration of the NO donor before ischemia, or to the preconditioned group with previous inhibition of AMPK, had no effect on energy metabolism. Both preconditioning and AICAR pretreatment, through AMPK activation, may be useful surgical and pharmacologic strategies aimed at reducing hepatic I/R injury.